• Merck shars (MRK) rose by 3% premarket on the back of positive information about Keytruda drug

Noticias del mercado

11 enero 2017

Merck shars (MRK) rose by 3% premarket on the back of positive information about Keytruda drug

Shares of pharmaceutical company Merck (MRK) show a strong growth in premarket trading. The reason for rise in price of securities, as reported by CNNMoney, is the fact that on Tuesday night, the company reported that the US Food and Drug Administration (US Food and Drug Administration) is considering an accelerated approval of the drug for the treatment of lung cancer, Keytruda.

MRK shares rose to $ 61.65 (+ 2.89%).

Enfoque del mercado
Material posted here is solely for information purposes and reliance on this may lead to losses. Past performances are not a reliable indicator of future results. Please read our full disclaimer
Abrir cuenta demo y página personal
Entiendo y acepto la Política de Privacidad y estoy de acuerdo con que mi nombre y datos de contacto sean procesados por TeleTrade y utilizados para contactarme en lo referente a: